logo
  

Protalix BioTherapeutics Inc. Q1 Loss decreases, but misses estimates

Protalix BioTherapeutics Inc. (PLX) released Loss for first quarter that decreased from the same period last year but missed the Street estimates.

The company's bottom line totaled -$2.29 million, or -$0.05 per share. This compares with -$5.48 million, or -$0.14 per share, in last year's first quarter.

Analysts on average had expected the company to earn $0.00 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 42.1% to $16.09 million from $11.32 million last year.

Protalix BioTherapeutics Inc. earnings at a glance (GAAP) :

-Earnings (Q1): -$2.29 Mln. vs. -$5.48 Mln. last year.
-EPS (Q1): -$0.05 vs. -$0.14 last year.
-Analyst Estimates: $0.00
-Revenue (Q1): $16.09 Mln vs. $11.32 Mln last year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT